VELOCITY A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute STEMI Undergoing PCI Gregg W. Stone, MD Columbia University Medical.

Slides:



Advertisements
Similar presentations
A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Advertisements

Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Cold saline and endovascular cooling induces rapid hypothermia before reperfusion in STEMI patients treated with primary PCI, is safe and reduces infarct.
Stone p2203/Abstract/ Conclusions
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
Post-Event Hypothermia Julie Swain M.D. Cardiovascular Surgeon Consultant to the FDA Circ System Devices Advisory Panel Sept 2004 DRAFT slides.
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
Hypothermia in awake STEMI patients:
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
ADAPT-DES One-Year Results Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents A Large-Scale, Multicenter, Prospective, Observational Study.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Lisette Okkels Jensen, Per Thayssen, Henrik Steen Hansen, Evald Høj Christiansen, Hans Henrik Tilsted, Lars Romer Krusell, Anton Boel Villadsen, Anders.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Late Clinical Outcomes after Bioresorbable or Permanent Polymer Everolimus-Eluting Stents: 2-Year Results from the EVOLVE II Randomized Trial Dean J.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Total Occlusion Study of Canada (TOSCA-2) Trial
The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis.
Updates From NOTION: The First All-Comer TAVR Trial
Main Arena IV - Plenary Session XXVII: First Reports #4
For the HORIZONS-AMI Investigators
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
The Tryton Bifurcation Trial:
DES Should be Used as the Default Stent in ACS!
OCT-Guided PCI What needs to be done to establish criteria?
The EUROMAX trial is supported by The Medicines Company
Preliminary results of the Elutax SV Italian registry
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
Thomas Stiermaier, MD; Suzanne de Waha, MD;
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Presented by Dr. Leif Thuesen
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
Giuseppe Biondi Zoccai, MD
The HORIZONS-AMI Trial
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
American College of Cardiology Presented by Dr. Michel R. Le May
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Translation Pathway for Coronary Stent Development- Clinical Endpoints
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
Hypothermia in awake STEMI patients:
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

VELOCITY A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute STEMI Undergoing PCI Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation On behalf of Graham Nichol, Warren Strickland, David Shavelle, Akiko Maehara, Ori Ben-Yehuda, Philippe Genereux, Ovidiu Dressler, Rupa Parvataneni, Melissa Nichols, John McPherson, Gérald Barbeau, Abhay Laddu, Jo Ann Elrod, Griffeth W. Tully, and Russell Ivanhoe

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Consultant Velomedix All faculty disclosures are available on the CRF Events App and online at www.crf.org/tct

Background Systemic hypothermia (≤34.9°C) may reduce infarct size if established before reperfusion Peritoneal lavage has a well-established safety profile for diagnosis of blunt abdominal injury in patients with trauma, and for treatment of accidental hypothermia, end-stage renal disease, and cancer The large surface area of the bowel may facilitate rapid hypothermia, safely reducing infarct size

Velomedix Automated Peritoneal Lavage System Refrigerator (disposable fluid bags inside) Solid state cooling, warming Touchscreen interface Esophageal core temperature probe Peritoneal catheter Lavage fluid line Controller console Hypothermia to 34.9°C is induced before PCI by lavaging the peritoneal cavity with temperature-controlled 2.5 - 4.5 liters of lactated Ringer’s solution Further cooling occurs to a target temperature of 32.5°C, which is maintained for 3 hours post-PCI, after which the system initiates active re- warming and then fluid drainage Shivering prophylaxis and treatment Pre-PCI: Buspirone; meperidine, forced-air warming blanket If needed: Fentanyl, magnesium, dexmedetomidine

MRI Results at Day 3-5 Control (n=20) Hypothermia (n=26) P value Time from PCI (days) 4 (3, 4) 4 (3, 5) 0.53 LV myocardial mass (grams) 125.5 (109.5, 135,5) 123 (107, 142) 0.80 Area at risk (grams) 35.1 (20.4, 50.5) 34.2 (26, 51.6) 0.56 Area at risk (% LV mass) 26.8 (16.7, 40.6) 26.1 (22.7, 34.4) 0.69 Infarct mass (grams) 20.8 (10.9, 27.6) 22.2 (15.6, 30.1) 0.44 Infarct mass/area at risk (%) 55.8 (43.8, 67.2) 67.3 (48.9, 73.3) 0.36 Myocardial salvage (%) 44.2 (32.8, 56.2) 32.7 (26.7, 51.1) Primary efficacy endpoint: Infarct size (% total LV mass) 16.1 (10.0, 22.2) 17.2 (15.1, 20.6) 0.54 MVO (grams) 0 (0, 0.2) 0 (0, 0.7) 0.57 MVO (% total LV mass) 0 (0, 0.5) 0.64 LV end-diastolic volume (mL) 161 (137.5, 172) 159 (125, 191) LV end-systolic volume (mL) 83.3 (66.8, 102) 81.9 (71, 119) 0.63 LV stroke volume (mL) 75.2 (61.4, 81.5) 75.4 (61.1, 84) 0.78 LV ejection fraction (%) 46.3 (42.6, 50.6) 43.3 (37.4, 52) 0.37 Abnormal wall motion score 8 (4, 11.5) 8 (6, 10) 0.52

Major Adverse Cardiac Events 30-day events Control (n=26) Hypothermia (n=28) P value Composite MACE 3 (10.7%) 0.24 Cardiac death 1 (3.6%)* >0.99 Reinfarction 1 (3.6%)** Ischemia-driven TVR 3 (10.7%)** Stent thrombosis Acute (≤24 hrs) 2 (7.1%) 0.49 Subacute (1-30d) 1 (3.6%) Definite Probable - *Pt with aortic dissection mimicking STEMI died after surgery (no PCI or hypothermia); **Due to stent thrombosis

Conclusions Controlled systemic hypothermia through automated peritoneal lavage may be rapidly established in pts with evolving STEMI undergoing primary PCI at the expense of a modest increase in door-to-balloon time In the present randomized trial, peritoneal hypothermia was associated with an increased rate of adverse events (including stent thrombosis) without reducing infarct size